The Raven technology platform has generated well-characterized, high-affinity monoclonal antibodies to proteins on the cell surface that can be used to quickly identify and validate targets. The platform has delivered an extensive library of antibodies targeting novel and recognized antigens. Raven is initially focusing on antibody-based therapeutics targeting lung, colon, pancreatic, prostate, breast, and ovarian cancer.
George Schreiner, CEO of Raven, said: “Through our collaboration with Monogram we hope ultimately to accelerate the development of targeted oncology therapeutics.”